43. Nutritional status and associated factors in children with juvenile idiopathic arthritis at the Children’s Hospital of Vietnam
Main Article Content
Abstract
Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease and the leading cause of acquired disability in children. A cross-sectional descriptive study was conducted on 126 pediatric patients aged ≤ 16 years old diagnosed with JIA and treated at the Department of Immunology - Allergy - Rheumatology, the Children’s Hospital of Viet Nam, from June 2024 to May 2025. The study aimed to assess nutritional status and investigate associated factors. The majority (89.9%) was children over 5 years old with a mean age of 9.8 ± 3.6 years old, Most patients had a disease duration of ≥ 2 years (63.5%). The prevalence of undernutrition in the forms of underweight, stunting, wasting, and overweight/obesity was 7.9%, 27%, 9.5%, and 22.2%, respectively. No statistically significant association was found between nutritional status and factors such as age, sex, disease duration, treatment regimen, or clinical subtype. However, stunting, underweight, and overweight/obesity were more common among patients with active disease. A significant association was observed between disease activity and weight-for-age (p = 0.009) as well as weight-for-height z-scores (p = 0.025).
Article Details
Keywords
Juvenile idiopathic arthritis, nutritional status
References
2. Harrold LR, Salman C, Shoor S, et al. Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996–2009. J Rheumatol. 2013; 40(7): 1218-1225. doi:10.3899/jrheum.120661.
3. Grammatikopoulou MG, Gkiouras K, Syrmou V, et al. Nutritional Aspects of Juvenile Idiopathic Arthritis: An A to Z for Dietitians. Children. 2023; 10(2): 203. doi:10.3390/children10020203.
4. Zandonadi RP. An Overview of Nutritional Aspects in Juvenile Idiopathic Arthritis. Nutrients. 2022; 14(20): 4412. doi:10.3390/nu14204412.
5. Stawicki MK, Abramowicz P, Góralczyk A, et al. Prevalence of Vitamin D Deficiency in Patients Treated for Juvenile Idiopathic Arthritis and Potential Role of Methotrexate: A Preliminary Study. Nutrients. 2022; 14(8): 1645. doi:10.3390/nu14081645.
6. Bloem M. The 2006 WHO child growth standards. BMJ. 2007; 334(7596): 705-706. doi:10.1136/bmj.39155.658843.BE.
7. Shoop-Worrall SJW, Verstappen SMM, Baildam E, et al. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann Rheum Dis. 2017; 76(8): 1381-1388. doi:10.1136/annrheumdis-2016-210511.
8. Pelajo CF, Lopez-Benitez JM, Miller LC. Obesity and disease activity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2012; 10:3. doi:10.1186/1546-0096-10-3.
9. Gicchino MF, Marzuillo P, Melone R, et al. The dual role of body mass index on Juvenile Idiopathic Arthritis course: a pediatric experience. Eur J Pediatr. 2024; 183(2): 809-813. doi:10.1007/s00431-023-05348-8
10. Bechtold S, Roth J. Natural history of growth and body composition in juvenile idiopathic arthritis. Horm Res. 2009; 72 Suppl 1:13-19. doi:10.1159/000229758.
11. d’Angelo DM, Di Donato G, Breda L, et al. Growth and puberty in children with juvenile idiopathic arthritis. Pediatr Rheumatol. 2021; 19(1): 28. doi:10.1186/s12969-021-00521-5.
12. Więch P, Sałacińska I, Bazaliński D, et al. Body composition and phase angle as an indicator of nutritional status in children with juvenile idiopathic arthritis. Pediatric Rheumatology. 2018; 16(1): 82. doi:10.1186/s12969-018-0297-y.
13. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis & Rheumatology. 2019; 71(6): 846-863. doi:10.1002/art.40884.
14. Neto A, Mourão AF, Oliveira-Ramos F, et al. Association of body mass index with Juvenile Idiopathic Arthritis disease activity: a Portuguese and Brazilian collaborative analysis. Acta Reumatol Port. 2021; 46(1): 7-14.